Analysts Set Expectations for RYTM Q4 Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Equities research analysts at Leerink Partnrs issued their Q4 2026 EPS estimates for Rhythm Pharmaceuticals in a note issued to investors on Sunday, July 13th. Leerink Partnrs analyst F. Khurshid anticipates that the company will post earnings per share of ($0.62) for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share.

Several other equities analysts have also weighed in on RYTM. Guggenheim reaffirmed a “buy” rating on shares of Rhythm Pharmaceuticals in a research report on Thursday, July 10th. Wells Fargo & Company raised their price objective on shares of Rhythm Pharmaceuticals from $91.00 to $129.00 and gave the company an “overweight” rating in a research report on Thursday, July 10th. Canaccord Genuity Group raised their price objective on shares of Rhythm Pharmaceuticals from $81.00 to $92.00 and gave the company a “buy” rating in a research report on Tuesday, April 8th. The Goldman Sachs Group started coverage on shares of Rhythm Pharmaceuticals in a research report on Thursday, July 10th. They set a “buy” rating and a $97.00 price objective on the stock. Finally, Oppenheimer set a $110.00 price objective on shares of Rhythm Pharmaceuticals and gave the company an “outperform” rating in a research report on Thursday, July 10th. Fourteen investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $91.00.

Rhythm Pharmaceuticals Stock Performance

Shares of RYTM opened at $89.36 on Tuesday. The firm has a market cap of $5.69 billion, a PE ratio of -31.80 and a beta of 2.26. The firm’s 50 day moving average price is $65.37 and its 200 day moving average price is $59.75. Rhythm Pharmaceuticals has a twelve month low of $40.61 and a twelve month high of $94.80.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.12). The company had revenue of $37.72 million for the quarter, compared to analyst estimates of $40.43 million. Rhythm Pharmaceuticals had a negative return on equity of 739.62% and a negative net margin of 123.26%. The business’s revenue for the quarter was up 25.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($2.35) earnings per share.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of RYTM. Charles Schwab Investment Management Inc. boosted its stake in Rhythm Pharmaceuticals by 1.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 440,250 shares of the company’s stock worth $24,645,000 after buying an additional 6,384 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Rhythm Pharmaceuticals during the fourth quarter worth $218,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Rhythm Pharmaceuticals during the fourth quarter worth $341,000. Swiss National Bank boosted its stake in Rhythm Pharmaceuticals by 1.0% during the fourth quarter. Swiss National Bank now owns 90,200 shares of the company’s stock worth $5,049,000 after buying an additional 900 shares in the last quarter. Finally, Cibc World Markets Corp acquired a new stake in Rhythm Pharmaceuticals during the fourth quarter worth $287,000.

Insiders Place Their Bets

In other news, insider Joseph Shulman sold 7,969 shares of the firm’s stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $77.78, for a total value of $619,828.82. Following the sale, the insider owned 8,509 shares in the company, valued at approximately $661,830.02. This trade represents a 48.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Christopher Paul German sold 3,817 shares of the firm’s stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $80.75, for a total transaction of $308,222.75. Following the completion of the sale, the chief accounting officer owned 922 shares in the company, valued at approximately $74,451.50. The trade was a 80.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 93,673 shares of company stock valued at $7,118,510 in the last 90 days. 6.10% of the stock is currently owned by corporate insiders.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.